Brokerages Set Tango Therapeutics, Inc. (NASDAQ:TNGX) PT at $14.80

Tango Therapeutics, Inc. (NASDAQ:TNGX) has earned an average rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $14.80.

Several equities analysts have issued reports on TNGX shares. Wall Street Zen upgraded shares of Tango Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Guggenheim upped their target price on Tango Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Tango Therapeutics in a research note on Monday, October 27th. B. Riley Financial lifted their price target on Tango Therapeutics from $8.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tango Therapeutics in a report on Wednesday, January 21st.

Insider Buying and Selling

In other news, CFO Daniella Beckman sold 10,317 shares of the company’s stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total value of $126,486.42. Following the completion of the sale, the chief financial officer directly owned 184,297 shares of the company’s stock, valued at approximately $2,259,481.22. This represents a 5.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barbara Weber sold 30,519 shares of the firm’s stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $374,162.94. Following the transaction, the director directly owned 1,629,254 shares in the company, valued at approximately $19,974,654.04. This represents a 1.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 59,288 shares of company stock worth $726,871 in the last 90 days. Company insiders own 7.50% of the company’s stock.

Institutional Investors Weigh In On Tango Therapeutics

Several hedge funds have recently modified their holdings of the stock. CWM LLC raised its position in Tango Therapeutics by 182.2% during the 2nd quarter. CWM LLC now owns 4,905 shares of the company’s stock worth $25,000 after buying an additional 3,167 shares during the last quarter. Global Retirement Partners LLC acquired a new position in shares of Tango Therapeutics during the fourth quarter worth about $35,000. Dynamic Technology Lab Private Ltd increased its stake in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after acquiring an additional 15,037 shares during the period. Legal & General Group Plc raised its holdings in Tango Therapeutics by 30.7% during the second quarter. Legal & General Group Plc now owns 6,985 shares of the company’s stock worth $36,000 after purchasing an additional 1,640 shares in the last quarter. Finally, Ameritas Investment Partners Inc. lifted its position in Tango Therapeutics by 78.8% in the second quarter. Ameritas Investment Partners Inc. now owns 7,830 shares of the company’s stock valued at $40,000 after purchasing an additional 3,452 shares during the period. 78.99% of the stock is owned by institutional investors and hedge funds.

Tango Therapeutics Trading Up 1.8%

TNGX stock opened at $12.90 on Monday. The stock has a market cap of $1.74 billion, a P/E ratio of -13.87 and a beta of 1.75. Tango Therapeutics has a twelve month low of $1.03 and a twelve month high of $13.48. The company’s 50 day moving average is $10.68 and its two-hundred day moving average is $8.83.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.